Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today the appointment of Kevin Finney to the position of President and Chief Operating Officer.
January 24, 2019
· 4 min read